Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.
The UK meningococcal serogroup C conjugate (MCC) vaccine program has successfully controlled serogroup C disease, due to high vaccine effectiveness and substantial herd immunity. However, children immunised at 2, 3 and 4 months of age receive only short-term direct protection and may be at risk of disease 15 months after vaccination. To investigate this we applied a mathematical model to predict the future epidemiology of serogroup C disease, with and without changes to the immunization schedule. Only a few cases of serogroup C disease were predicted to occur over the next few years because of persisting herd immunity, even without a change to the vaccine schedule. The inclusion of a booster dose is likely to improve the impact of the MCC program and reducing the number of doses in infancy will improve cost-effectiveness and create space in the schedule for the addition of other vaccines.
Item Type | Article |
---|---|
Keywords | Adolescent, Algorithms, Carrier State/epidemiology/immunology, Cost-Benefit Analysis, England/epidemiology, Female, Forecasting, Humans, Immunity, Herd, Immunization Schedule, Male, Meningococcal Infections/epidemiology/*immunology/*prevention & control, Meningococcal Vaccines/economics/*immunology, Models, Statistical, Neisseria lactamica/immunology, Vaccines, Conjugate/economics/immunology, Wales/epidemiology, Adolescent, Algorithms, Carrier State, epidemiology, immunology, Cost-Benefit Analysis, England, epidemiology, Female, Forecasting, Humans, Immunity, Herd, Immunization Schedule, Male, Meningococcal Infections, epidemiology, immunology, prevention & control, Meningococcal Vaccines, economics, immunology, Models, Statistical, Neisseria lactamica, immunology, Vaccines, Conjugate, economics, immunology, Wales, epidemiology |
ISI | 243979200004 |